# Immune Thrombocytopenia

Diagnose ITP only after confirming true isolated thrombocytopenia and excluding urgent thrombotic, marrow, infectious, drug-related, and pregnancy-specific causes. Management is driven by bleeding, platelet trajectory, treatment requirements, comorbidity, and durability goals rather than platelet count alone.

**Clinical question:** How should physicians confirm ITP, triage bleeding risk, and select initial and subsequent therapy?

Updated: 2026-08-24T17:34:12.527099+00:00

## What matters in practice
- ITP is a diagnosis of exclusion defined by platelet count below 100 × 10^9/L with otherwise isolated thrombocytopenia; confirm the result and review a peripheral smear before attributing thrombocytopenia to ITP. [3][12][16][20][23]
- Life-threatening bleeding warrants immediate combination treatment with corticosteroids, IVIG, and platelet transfusion irrespective of the platelet count. [3]
- In adults without major bleeding, treatment decisions should incorporate bleeding, platelet trend, antiplatelet or anticoagulant exposure, trauma or procedure needs, and comorbid hemostatic defects; bleeding risk rises particularly below 20 × 10^9/L. [8][16][19]
- Use a short corticosteroid course for newly diagnosed adult ITP requiring treatment; prednisone 1 mg/kg daily, maximum 80 mg, for 2 weeks with discontinuation by 6 to 8 weeks, or dexamethasone 40 mg daily for 4 days are cited regimens. [8][24]
- Persistent or chronic disease after first-line therapy should trigger reassessment for a misdiagnosis or secondary cause and a shared choice among thrombopoietin-receptor agonists, rituximab, fostamatinib, or splenectomy. [12][22][24]

## Triage bleeding and exclude thrombocytopenic emergencies

Treat active critical bleeding while the diagnostic evaluation proceeds.

For intracranial, gastrointestinal, hemodynamically significant, or otherwise life-threatening bleeding in suspected ITP, give corticosteroids, IVIG, and platelet transfusion as combination therapy regardless of the presenting platelet count. [3] Obtain a CBC with differential and manual peripheral smear immediately; ITP should show isolated thrombocytopenia, whereas anemia, leukopenia, abnormal leukocytes, schistocytes, or dysplastic cells redirect the evaluation. [12][21][23]

Do not label a patient as having ITP until pseudothrombocytopenia has been excluded. Repeat the CBC to confirm thrombocytopenia and inspect the smear for platelet clumping or rosette formation. [12][20][22] Schistocytes should prompt evaluation for thrombotic microangiopathy rather than empiric ITP treatment; pregnancy-associated thrombocytopenia requires urgent consideration of hypertensive disorders of pregnancy and thrombotic thrombocytopenic purpura. [14][20][23]

Bleeding risk is not determined by a single platelet threshold, but risk increases below 20 × 10^9/L. [8] In a patient with platelets above 50 × 10^9/L and no bleeding, observation is generally appropriate unless an invasive intervention or concomitant antiplatelet therapy necessitates a higher count. [19] A platelet count near or above 30 × 10^9/L may be acceptable in selected adults without bleeding or additional hemostatic risks, while treatment is rarely indicated above that level in the absence of platelet dysfunction, another hemostatic defect, trauma, or planned surgery. [15][16]
- Escalate beyond an ITP pathway when smear review shows schistocytes, blasts, immature leukocytes, dysplasia, marked giant platelets, or platelet clumping. [12][21][22][23]
- Treat a bleeding phenotype and procedural requirement, not the platelet number in isolation. [8][16][19]
- In pregnancy, first distinguish gestational thrombocytopenia from hypertensive disorders, thrombotic thrombocytopenic purpura, and other pregnancy-related causes before diagnosing ITP. [14]

*Findings that should interrupt a presumptive ITP diagnosis and change the next diagnostic action. [12][14][20][21][22][23]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Platelet clumping or rosette formation on smear | Pseudothrombocytopenia is possible. [12][22] | Repeat CBC and verify a true platelet count before treatment. [20] |
| Schistocytes | Consider thrombotic microangiopathy rather than isolated immune-mediated platelet destruction. [12][20][23] | Urgently evaluate for thrombotic thrombocytopenic purpura or hemolytic uremic syndrome. [20] |
| Blasts, immature leukocytes, dysplastic cells, or unexplained cytopenias | Marrow disease, including myelodysplastic syndrome or hematologic malignancy, becomes more likely. [12][21][22] | Obtain hematology assessment and consider bone marrow examination. [21][22] |
| Marked giant platelets | Consider inherited macrothrombocytopenia or marrow-failure syndromes. [12][21][22] | Review personal and family history and pursue directed hematologic evaluation. [12][22] |
| Pregnancy with thrombocytopenia | ITP is only one diagnostic branch; hypertensive disorders and thrombotic thrombocytopenic purpura require exclusion. [14] | Apply a pregnancy-specific thrombocytopenia evaluation before assigning ITP. [14] |

## Confirm isolated thrombocytopenia and search for secondary ITP

No platelet autoantibody assay establishes the diagnosis.

Use the clinical pattern of platelet count below 100 × 10^9/L, history, physical examination, CBC, and peripheral smear to establish a presumptive diagnosis after alternative causes have been excluded. [3][12][16][22][23] Typical ITP has reduced platelet number with normal or increased platelet size and no schistocytes or other major smear abnormalities. [22][23]

Obtain HIV and hepatitis C testing in the initial evaluation of isolated thrombocytopenia. [19][20][22] HIV, hepatitis B and C serologies, antinuclear antibody testing, and serum protein electrophoresis can identify clinical settings associated with secondary ITP; additional tests should be driven by the history, examination, and laboratory pattern. [19] A recent infection or vaccination may coincide with platelet decline, but an ITP attribution requires exclusion of other causes of thrombocytopenia. [15]

Do not routinely order platelet-antigen antibody testing: limited sensitivity and specificity make it unsuitable as a routine diagnostic test, and antiplatelet antibodies are detected in only about 50% to 60% of patients with ITP. [19][22] Failure to respond to first-line therapy should reopen the diagnosis and prompt a targeted review for autoimmune disease, infection, iatrogenic thrombocytopenia, marrow disease, and inherited thrombocytopenia rather than automatic sequential ITP therapy. [12][22]

Bone marrow examination is not a default test for typical isolated thrombocytopenia, but pursue it when anemia is unexplained by bleeding or iron deficiency, leukocyte count is below 3,000/µL or at least 10,000/µL, neutrophils are reduced, lymphocytes are elevated, or the smear shows immature or morphologically abnormal leukocytes. [21] Older adults and patients with apparent refractory ITP merit particular attention to myelodysplastic syndrome with isolated thrombocytopenia. [22]
- Document medication exposures, including heparin and other drugs temporally associated with thrombocytopenia, before diagnosing primary ITP. [16][20]
- Use liver-function tests, lactate dehydrogenase, and inflammatory markers when the clinical pattern suggests systemic disease; liver dysfunction, elevated lactate dehydrogenase, and inflammatory findings are atypical enough to require focused reassessment. [21]
- Classify as secondary ITP when an associated disorder or drug exposure is identified, because treating the underlying condition may alter the platelet strategy. [3][16]

*Focused initial evaluation for suspected adult ITP. [12][19][20][21][22][23]*

| Test or assessment | Decision use | Abnormal result that redirects care |
| --- | --- | --- |
| Repeat CBC with differential | Confirms thrombocytopenia and identifies anemia or leukocyte abnormalities. [20][23] | Non-isolated cytopenias require evaluation beyond ITP. [21][22] |
| Manual peripheral smear | Excludes clumping and detects morphologic alternatives. [12][23] | Schistocytes, blasts, dysplasia, or giant platelets redirect toward thrombotic microangiopathy, malignancy or MDS, or inherited thrombocytopenia. [12][21][22] |
| HIV and hepatitis C serologies | Recommended testing in isolated thrombocytopenia. [19][20][22] | Positive results support a secondary cause requiring condition-directed management. [16][19] |
| Hepatitis B serology, ANA, serum protein electrophoresis | Use to identify selected secondary ITP contexts. [19] | Abnormal findings should prompt disease-specific assessment rather than assuming primary ITP. [19] |
| Bone marrow examination | Reserve for atypical counts or smear findings and diagnostic uncertainty. [21][22] | Marrow abnormalities support an alternative diagnosis such as MDS or marrow failure. [22] |

## Select observation, corticosteroids, IVIG, or rescue therapy

Choose treatment intensity by bleeding, urgency of platelet rise, and treatment toxicity.

For adults requiring first-line treatment, use a short corticosteroid course rather than prolonged exposure. [8][24] A cited prednisone regimen is 1 mg/kg daily, maximum 80 mg, for 2 weeks; if platelet response exceeds 50 × 10^9/L, taper with a goal of stopping by 6 weeks and no later than 8 weeks. [8] Dexamethasone 40 mg daily for 4 days, repeated up to three times, is an alternative regimen. [8]

Use IVIG when corticosteroids are contraindicated, when a more rapid platelet increase is needed, or as part of combination treatment for life-threatening bleeding. [3][24] Anti-D immunoglobulin is also identified as an alternative first-line option in patients who cannot take or do not respond to corticosteroids. [24] Define a platelet response as at least 30 × 10^9/L with at least a twofold increase from baseline and absence of bleeding; a platelet count of at least 100 × 10^9/L is typically considered a complete response. [24]

In children with no or mild bleeding, observe regardless of platelet count, with bleeding and platelet monitoring by a pediatric hematologist; approximately 50% to 70% recover within 3 to 6 months without intervention. [17] For pediatric non-life-threatening mucosal bleeding or impaired health-related quality of life, prednisone 2 to 4 mg/kg/day, maximum 120 mg/day, for 5 to 7 days is a cited regimen; guidance summarized from U.S. recommendations favors corticosteroid courses no longer than 7 days. [2][17]
- Before prescribing corticosteroids, weigh diabetes, psychiatric vulnerability, infection risk, and anticipated need for repeated therapy; older adults may be particularly susceptible to treatment-related infection. [19]
- Use IVIG with corticosteroids and platelet transfusion for life-threatening bleeding; do not delay platelet transfusion while waiting for immune-directed treatment to act. [3]
- For pediatric ITP, bleeding and health-related quality of life—not platelet count alone—determine whether treatment is needed. [17]

*Initial management choices by bleeding severity and clinical urgency. [3][8][17][24]*

| Clinical scenario | Management | Key decision point |
| --- | --- | --- |
| Life-threatening bleeding | Corticosteroids plus IVIG plus platelet transfusion. [3] | Treat immediately regardless of platelet count. [3] |
| Adult requiring outpatient first-line treatment | Prednisone 1 mg/kg/day, maximum 80 mg, for 2 weeks with taper and discontinuation by 6 to 8 weeks; or dexamethasone 40 mg/day for 4 days. [8] | Avoid prolonged corticosteroid exposure. [24] |
| Need for rapid rise or corticosteroid contraindication | IVIG; anti-D immunoglobulin is another identified first-line alternative. [24] | Use when clinical urgency or corticosteroid intolerance changes the risk-benefit balance. [24] |
| Child with no or mild bleeding | Observation with platelet and bleeding monitoring. [17] | Observation is recommended regardless of platelet count. [17] |
| Child with non-life-threatening mucosal bleeding or impaired quality of life | Prednisone 2 to 4 mg/kg/day, maximum 120 mg/day, for 5 to 7 days. [17] | Use a short course rather than extended corticosteroids. [2][17] |

## Reassess diagnosis before selecting second-line treatment

Persistent thrombocytopenia after steroids is both a treatment and diagnostic decision point.

For persistent or chronic ITP after failure of first-line therapy, reassess the smear, secondary-cause testing, medication history, and need for bone marrow examination before assigning refractory disease. [12][21][22] Refractoriness particularly raises concern for misclassified myelodysplastic syndrome, inherited thrombocytopenia, autoimmune disease, infection, or iatrogenic thrombocytopenia. [12][22]

Second-line options used in adult chronic ITP include thrombopoietin-receptor agonists—eltrombopag, romiplostim, and avatrombopag—rituximab, fostamatinib, and splenectomy. [24] Treatment selection should prioritize the required platelet target, desire to avoid surgery or immunosuppression, prior response, infection risk, thrombotic risk, and patient preference because durable remission, treatment burden, and adverse-effect tradeoffs differ among approaches. [7][9][19][24]

Romiplostim is FDA-indicated for adults with ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. [1] In placebo-controlled adult trials, overall platelet response occurred in 88% of nonsplenectomized and 79% of splenectomized romiplostim-treated patients, compared with 14% and 0% with placebo; durable responses occurred in 61% and 38%, respectively. [1] Its labeling includes warnings regarding thrombotic and thromboembolic complications and loss of response. [1]

For children with non-life-threatening mucosal bleeding or impaired quality of life that is unresponsive to first-line therapy, or with chronic ITP, consider a thrombopoietin-receptor agonist such as eltrombopag or romiplostim; if no response occurs, rituximab is the next cited therapy. [17] In older adults, the infection consequences of corticosteroids, immunosuppressants, rituximab, and splenectomy should carry extra weight in treatment selection. [19]
- Do not treat a low count solely to normalize it; the clinical goals are bleeding control and prevention of severe bleeding. [8]
- Review thrombotic risk before and during thrombopoietin-receptor agonist treatment because romiplostim labeling warns of thrombotic and thromboembolic complications. [1]
- Reconsider splenectomy only after discussing irreversible procedural risk and increased infection susceptibility; infection risk in ITP is increased with immunosuppression and splenectomy. [19]

### Monitoring response and failure

Monitor platelet count and bleeding symptoms after each treatment change; response requires a platelet count of at least 30 × 10^9/L, at least a twofold increase from baseline, and no bleeding, whereas complete response is typically at least 100 × 10^9/L. [24] A declining count after an initial response should trigger review of adherence, concurrent infection or medication exposure, treatment toxicity, and the underlying diagnosis. [12][15][22]
- Monitor for infection during corticosteroid, rituximab, other immunosuppressive therapy, and after splenectomy, particularly in older adults. [19]
- With romiplostim, monitor for thrombotic or thromboembolic complications and loss of response. [1]

*Second-line treatment framework for persistent or chronic ITP. [1][17][19][24]*

| Option | When it fits | Important tradeoff or monitoring |
| --- | --- | --- |
| Eltrombopag, romiplostim, or avatrombopag | Options for adult chronic ITP after first-line failure; eltrombopag and romiplostim are options for children with persistent symptoms or chronic ITP after first-line therapy. [17][24] | Monitor platelet response; romiplostim labeling warns of thrombotic or thromboembolic complications and loss of response. [1] |
| Rituximab | An adult subsequent-treatment option and the cited next option for children not responding to a thrombopoietin-receptor agonist. [17][24] | Infection risk is important, especially in older adults. [19] |
| Fostamatinib | An adult chronic ITP option after first-line therapies fail. [24] | Select according to individual treatment goals and prior therapy. [24] |
| Splenectomy | An adult chronic ITP option after first-line failure. [24] | Balance procedural irreversibility with increased infection risk. [19] |

## Adapt the ITP pathway in pregnancy and older adults

Pregnancy and age change both the differential diagnosis and treatment harms.

In pregnancy, ITP may present for the first time or relapse; first rule out urgent pregnancy-related thrombocytopenic conditions before treating presumed ITP. [14] Treatment may be required for severe thrombocytopenia, bleeding, or preparation for delivery or neuraxial analgesia. [14] Prednisone or methylprednisolone and IVIG are first-line options described in pregnancy, with IVIG having a favorable pregnancy safety profile. [14]

For pregnancy-associated ITP requiring additional therapy, thrombopoietin-receptor agonists, rituximab, and selected immunosuppressants such as azathioprine have been used as second-line options, but selection should be individualized around maternal bleeding risk, delivery planning, and fetal considerations. [14] Avoid assuming that a platelet decline during pregnancy is ITP without evaluating for hypertensive disorders and thrombotic thrombocytopenic purpura. [14]

In older adults, use the same diagnostic fundamentals but lower the threshold for revisiting marrow disease and secondary causes when the presentation is atypical or treatment response is inadequate. [19][22] Bleeding is unusual above 50 × 10^9/L, supporting observation in the absence of a required higher platelet count for intervention; antiplatelet therapy may justify a higher platelet target, although the optimal target is uncertain. [19]
- Coordinate delivery and neuraxial planning early when pregnancy-associated ITP requires platelet-directed therapy. [14]
- In older adults, explicitly weigh infection risk from corticosteroids, immunosuppressive drugs, rituximab, and splenectomy before choosing subsequent therapy. [19]
- When antiplatelet drugs are necessary, individualized platelet targets may exceed those used for uncomplicated ITP. [19]

*Situations in which standard ITP decision thresholds require modification. [14][19][22]*

| Situation | Diagnostic modification | Management modification |
| --- | --- | --- |
| Pregnancy | Exclude hypertensive disorders of pregnancy and thrombotic thrombocytopenic purpura before diagnosing ITP. [14] | Treat for severe thrombocytopenia, bleeding, or delivery and neuraxial needs; prednisone or methylprednisolone and IVIG are first-line options. [14] |
| Older adult | Reconsider MDS and secondary causes when findings are atypical or disease appears refractory. [19][22] | Give additional weight to infection risks of corticosteroids, immunosuppression, rituximab, and splenectomy. [19] |
| Antiplatelet therapy or invasive intervention | Assess the need for a platelet target above an observation threshold. [16][19] | A higher platelet count may be needed; the optimal target with antiplatelet therapy remains uncertain. [19] |

## References
1. These highlights do not include all the information needed to use NPLATE safely and effectively.
       
      See full prescribing information for NPLATE.
      
       
      
      N
      PLATE
      
         ®
      
       (romiplostim)
       for injection
      , for subcutaneous 
      use
      
      Initial U.S. Approval: 2008 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c45f9a58-37c1-4f76-8e36-97d38c577037&type=display
2. 298 Overview on the current management guidelines of immune thrombocytopenia in children | Archives of Disease in Childhood — adc.bmj.com — https://adc.bmj.com/content/106/Suppl_2/A126.1
3. Immune thrombocytopenia - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/zh-cn/138
4. Rilzabrutinib, an Oral BTK Inhibitor, in Immune ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa2110297
5. Ianalumab plus Eltrombopag in Immune Thrombocytopenia — www.nejm.org — https://www.nejm.org/doi/pdf/10.1056/NEJMoa2515168
6. A chronic refractory ITP case report: Heliyon — www.cell.com — https://www.cell.com/heliyon/fulltext/S2405-8440(23)00669-2
7. International consensus report on the investigation and management of primary immune thrombocytopenia - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0006497120493486
8. Current approaches for the diagnosis and management of immune thrombocytopenia — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0953620522004125
9. Standardized Clinical Assessment and Management Plans (SCAMPs): Perspectives on a New Method to Understand Treatment Decisions and Outcomes in Immune Thrombocytopenia - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S003719631300036X
10. The new era of primary immune thrombocytopenia management in adults: A narrative review of current and emerging treatments — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0268960X25000451
11. Primary Immune Thrombocytopenia — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/abs/10.1002/9781444323160.ch49
12. Primary immune thrombocytopenia: a ‘diagnosis of... : Blood Coagulation & Fibrinolysis — journals.lww.com — https://journals.lww.com/bloodcoagulation/fulltext/2022/09000/primary_immune_thrombocytopenia__a__diagnosis_of.1.aspx
13. Guidelines for Pediatric Immune Thrombocytopenia - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK603670
14. A practical approach to immune thrombocytopenia in pregnancy | Hematology, ASH Education Program | American Society of Hematology — ashpublications.org — https://ashpublications.org/hematology/article/2025/1/503/556840/A-practical-approach-to-immune-thrombocytopenia-in
15. Consensus Guidelines Outline Treatment of ITP Related to SARS-CoV-2 Infection, Vaccination | ASH Clinical News | American Society of Hematology — ashpublications.org — https://ashpublications.org/ashclinicalnews/news/6974/Consensus-Guidelines-Outline-Treatment-of-ITP
16. Immune Thrombocytopenia | Hematology, ASH Education Program | American Society of Hematology — ashpublications.org — https://ashpublications.org/hematology/article/2010/1/377/278337/Immune-Thrombocytopenia
17. Immune Thrombocytopenia - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK562282
18. Study Details | NCT07297563 | Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT07297563
19. Older Adults and Immune Thrombocytopenia - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9885884
20. Thrombocytopenia - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK542208
21. Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10770234
22. The Challenge for a Correct Diagnosis of Refractory Thrombocytopenia: ITP or MDS with Isolated Thrombocytopenia? — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11048195
23. Assessment and Management of Immune Thrombocytopenia (ITP) in the Emergency Department: Current Perspectives — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8809484
24. Treatment of Adult Patients With Chronic Immune Thrombocytopenia After Failure of First-Line Therapies - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK595123

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.